INTRODUCTION: Treatment with the humanized anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in glioblastoma patients suppresses contrast enhancement via the reduction of vascular permeability, which does not necessarily indicate real reduction of tumor cell mass. Therefore, other imaging criteria are needed to recognize tumor growth under bevacizumab more reliably. It is still unknown, whether quantitative T1 mapping is useful to monitor the effects of anti-angiogenic therapy or to indicate a tumor progression earlier and more reliable compared to conventional magnetic resonance imaging (MRI) sequences. This raised the question whether quantitative T1 mapping is more suitable to monitor treatment effects of bevacizumab. METHODS: Conventional and quantitative MRI was performed on six consecutive patients with recurrent glioblastoma before treatment with bevacizumab and every 8 weeks thereafter until further tumor progression. Quantitative T1 maps before and after intravenous application of contrast agent and quantitative T2 maps were performed to calculate serial differential maps and subtraction maps from one time point, subtracting contrast-enhanced T1 maps from non-contrast T1 maps. RESULTS: In five illustrative cases, tumor progression was documented earlier in differential T1 relaxation time (DiffT1) and T2 relaxation time (DiffT2) maps before changes in the conventional MRI studies were obvious. Four patients showed previous prolongation of T1 relaxation time in the DiffT1 maps, suggesting tumor progression, and subtraction maps revealed faint contrast enhancement matching with the areas of T1 prolongation. CONCLUSION: Our results emphasize that quantitative relaxation time mapping could be a promising method for tumor monitoring in glioblastoma patients under anti-angiogenic therapy. Quantitative T1 mapping seems to detect enhancing tumor earlier than conventional contrast-enhanced T1-weighted images.
INTRODUCTION: Treatment with the humanized anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in glioblastomapatients suppresses contrast enhancement via the reduction of vascular permeability, which does not necessarily indicate real reduction of tumor cell mass. Therefore, other imaging criteria are needed to recognize tumor growth under bevacizumab more reliably. It is still unknown, whether quantitative T1 mapping is useful to monitor the effects of anti-angiogenic therapy or to indicate a tumor progression earlier and more reliable compared to conventional magnetic resonance imaging (MRI) sequences. This raised the question whether quantitative T1 mapping is more suitable to monitor treatment effects of bevacizumab. METHODS: Conventional and quantitative MRI was performed on six consecutive patients with recurrent glioblastoma before treatment with bevacizumab and every 8 weeks thereafter until further tumor progression. Quantitative T1 maps before and after intravenous application of contrast agent and quantitative T2 maps were performed to calculate serial differential maps and subtraction maps from one time point, subtracting contrast-enhanced T1 maps from non-contrast T1 maps. RESULTS: In five illustrative cases, tumor progression was documented earlier in differential T1 relaxation time (DiffT1) and T2 relaxation time (DiffT2) maps before changes in the conventional MRI studies were obvious. Four patients showed previous prolongation of T1 relaxation time in the DiffT1 maps, suggesting tumor progression, and subtraction maps revealed faint contrast enhancement matching with the areas of T1 prolongation. CONCLUSION: Our results emphasize that quantitative relaxation time mapping could be a promising method for tumor monitoring in glioblastomapatients under anti-angiogenic therapy. Quantitative T1 mapping seems to detect enhancing tumor earlier than conventional contrast-enhanced T1-weighted images.
Authors: L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen Journal: AJNR Am J Neuroradiol Date: 2011-03-10 Impact factor: 3.825
Authors: Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Alexandra Seewann; Hugo Vrenken; Paul van der Valk; Erwin L A Blezer; Dirk L Knol; Jonas A Castelijns; C H Polman; Petra J W Pouwels; Frederik Barkhof; Jeroen J G Geurts Journal: Arch Neurol Date: 2009-05
Authors: Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith Journal: Neuroimage Date: 2011-09-16 Impact factor: 6.556
Authors: An Claes; Giulio Gambarota; Bob Hamans; Olaf van Tellingen; Pieter Wesseling; Cathy Maass; Arend Heerschap; William Leenders Journal: Int J Cancer Date: 2008-05-01 Impact factor: 7.396
Authors: E Hattingen; A Jurcoane; M Nelles; A Müller; U Nöth; B Mädler; P Mürtz; R Deichmann; H H Schild Journal: Clin Neuroradiol Date: 2015-07-30 Impact factor: 3.649
Authors: Sen Ma; Christopher T Nguyen; Fei Han; Nan Wang; Zixin Deng; Nader Binesh; Franklin G Moser; Anthony G Christodoulou; Debiao Li Journal: Magn Reson Med Date: 2019-11-25 Impact factor: 4.668
Authors: Nicole Schwendener; Christian Jackowski; Frederick Schuster; Anders Persson; Marcel J Warntjes; Wolf -Dieter Zech Journal: Int J Legal Med Date: 2017-06-17 Impact factor: 2.686
Authors: Siamak P Nejad-Davarani; Niloufar Zakariaei; Yongsheng Chen; E Mark Haacke; Newton J Hurst; M Salim Siddiqui; Lonni R Schultz; James M Snyder; Tobias Walbert; Carri K Glide-Hurst Journal: Med Phys Date: 2020-07-06 Impact factor: 4.071
Authors: C Badve; A Yu; S Dastmalchian; M Rogers; D Ma; Y Jiang; S Margevicius; S Pahwa; Z Lu; M Schluchter; J Sunshine; M Griswold; A Sloan; V Gulani Journal: AJNR Am J Neuroradiol Date: 2016-12-29 Impact factor: 3.825
Authors: Shihan Qiu; Yuhua Chen; Sen Ma; Zhaoyang Fan; Franklin G Moser; Marcel M Maya; Anthony G Christodoulou; Yibin Xie; Debiao Li Journal: Magn Reson Med Date: 2021-08-10 Impact factor: 4.668
Authors: Sen Ma; Nan Wang; Zhaoyang Fan; Marwa Kaisey; Nancy L Sicotte; Anthony G Christodoulou; Debiao Li Journal: Magn Reson Med Date: 2020-10-26 Impact factor: 4.668